Tural, D. Et Al. 2022. Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.3 , 585-591.

Tural, D., Selcukbiricik, F., Olmez, O. F., Sumbul, A. T., ERMAN, M., COŞKUN, H. Ş., ... ARTAÇ, M.(2022). Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.3, 585-591.

Tural, Deniz Et Al. "Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma," INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.3, 585-591, 2022

Tural, Deniz Et Al. "Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma." INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.3, pp.585-591, 2022

Tural, D. Et Al. (2022) . "Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma." INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.3, pp.585-591.

@article{article, author={Deniz Tural Et Al. }, title={Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma}, journal={INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY}, year=2022, pages={585-591} }